期刊
CANCER LETTERS
卷 325, 期 2, 页码 207-213出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.07.003
关键词
Hepatocellular carcinoma; Signal transducer and activator of transcription 3; Epithelial-mesenchymal transition; Doxorubicin; NSC 74859
类别
资金
- National Natural Science Funds for Distinguished Young Scholar [30925033]
- National Natural Science Funds of China [81101841, 81171884]
- Innovation and High-Level Talent Training Program of Department of Health of Zhejiang
Doxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs). which often undergo epithelial-mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may contribute to EMT during HCC chemotherapy. Low doses of NSC 78459 (a novel STAT3 inhibitor) have little effect on HCC cell proliferation, but efficiently inhibit STAT3. HuH-7, Hep3B, and HepG2 cells, with epithelial phenotypes, show significantly enhanced doxorubicin cytotoxicity following co-treatment with NSC 74859, whereas mesenchymal SNU-449 cells show no such enhancement. NSC 74859 inhibits STAT3 activity and suppressed doxorubicin-induced EMT in epithelial HCC cells. siRNA-mediated STAT3 knockdown resulted in EMT inhibition, which led to attenuation of NSC 74859-mediated chemosensitivity. Our data indicate NSC 74859 co-administration enhances doxorubicin cytotoxicity by inhibiting STAT3 in epithelial HCC cells. STAT3 deactivation and associated EMT attenuation contribute to the synergistic anti-tumor effects of combined NSC 74859/doxorubicin therapy. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据